Search Result

Results for "

A platelet phospholipase Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Phospholipase (16) Carbonic Anhydrase (4) FAP (1) Isotope-Labeled Compounds (2) Phosphatase (1) Phosphodiesterase (PDE) (1) Reference Standards (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (8) Inflammation/Immunology (6) Metabolic Disease (4) Neurological Disease (9)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Phospholipase Platelet-activating Factor Receptor (PAFR) Serpin PDGFR PNPLA3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108611

AACOCF3 4 Publications Verification Arachidonyl trifluoromethyl ketone	Phospholipase	Cardiovascular Disease
AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa *cytosolic phospholipase* A2 (cPLA2)*. AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits* glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .

HY-12807

FIPI 5 Publications Verification 5-Fluoro-2-indolyl deschlorohalopemide	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .

HY-130592

Compound 48/80 trihydrochloride 5 Publications Verification C48/80 trihydrochloride	Phospholipase	Neurological Disease
Compound 48/80 trihydrochloride (C48/80 trihydrochloride) is a mixture of condensation products of N-methyl-p-methoxyphenethylamine with formaldehyde. Compound 48/80 trihydrochloride is also a histamine releaser and a mast cell degranulator. Compound 48/80 inhibits *phosphatidylinositol-specific phospholipase* C** activity from human platelets .

HY-N1393

2-Methoxybenzoic acid NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether	Carbonic Anhydrase Phospholipase	Cardiovascular Disease
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether) is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A₂ phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .

HY-102004

Rilapladib 3 Publications Verification SB 659032	Phospholipase	Neurological Disease Inflammation/Immunology
Rilapladib (SB 659032) is a selective Lp-PLA₂ (lipoprotein-associated phospholipase A₂) inhibitor with an IC₅₀ of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist .

HY-120621

BMS-229724	Phospholipase	Inflammation/Immunology
BMS-229724 is an orally active and tight-binding cytosolic phospholipase A₂ (cPLA₂) inhibitor with an IC₅₀ of 2.8 μM. BMS-229724 can inhibit the production of arachidonic acid and eicosanoids in U937 cells, neutrophils, platelets, and other cells. BMS-229724 has anti-inflammatory activity and can be used in the research of diseases such as skin inflammation .

HY-142670

Lp-PLA2-IN-5	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-5 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 32) .

HY-142669

Lp-PLA2-IN-4	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-4 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 38) .

HY-12807A

FIPI hydrochloride 5-Fluoro-2-indolyl deschlorohalopemide hydrochloride	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
FIPI hydrochloride is a phospholipase D (PLD) inhibitor with an IC₅₀ for PLD1 and PLD2 of about 25 nM. FIPI hydrochloride regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI hydrochloride can be used in cancer research. In addition, FIPI hydrochloride can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .

HY-142779

Lp-PLA2-IN-11	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-11 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2014114249A1, compound E145) .

HY-142778

Lp-PLA2-IN-10	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .

HY-N1393R

2-Methoxybenzoic acid (Standard) NSC 3778 (Standard); O-Methylsalicylic acid (Standard); Salicylic acid methyl ether (Standard)	Reference Standards Carbonic Anhydrase Phospholipase	Cardiovascular Disease
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether) (Standard) is the analytical standard of 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A₂ phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .

HY-N1393S

2-Methoxybenzoic acid-13C6 NSC 3778-¹³C₆; O-Methylsalicylic acid-¹³C₆; Salicylic acid methyl ether-¹³C₆	Isotope-Labeled Compounds Carbonic Anhydrase Phospholipase	Cardiovascular Disease
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)- ¹³C₆ is the ¹³C-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A₂ phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .

HY-182452

U 84569	Phosphodiesterase (PDE) Phospholipase	Cardiovascular Disease
U 84569 is a potent low-Km cAMP-dependent Phosphodiesterase inhibitor, with an IC₅₀ value of 300 nM in platelet cytosol. By inhibiting phosphodiesterase and elevating cAMP levels, U 84569 indirectly blocks receptor-mediated Phospholipase C activation, thereby inhibiting platelet aggregation .

HY-182434

CL 118326	Phosphatase FAP	Inflammation/Immunology
CL 118326 is a potent, selective, competitive inhibitor of mammalian pancreatic phospholipase A₂ (PLA₂) and a weak antagonist of platelet-activating factor receptor (PAF receptor). CL 118326 competitively inhibits mammalian pancreatic PLA₂ (porcine: IC₅₀ = 1.55 μg/mL), and shows no activity against snake venom or bee venom PLA₂. CL 118326 inhibits PAF-induced and thrombin-induced platelet aggregation, as well as the release of leukotriene (LTC₄) and histamine from basophil-enriched leukocytes. CL 118326 can be used for research on inflammation and allergic reactions .

HY-102004R

Rilapladib (Standard) SB 659032 (Standard)	Reference Standards Phospholipase	Neurological Disease Inflammation/Immunology
Rilapladib (Standard) is the analytical standard of Rilapladib (HY-102004). This product is intended for research and analytical applications. Rilapladib (SB 659032) is a selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor with an IC₅₀ of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist .

HY-N1393S1

2-Methoxybenzoic acid-d3 NSC 3778-d₃; O-Methylsalicylic acid-d₃; Salicylic acid methyl ether-d₃	Isotope-Labeled Compounds Carbonic Anhydrase Phospholipase	Cardiovascular Disease
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)-d₃ is deuterium-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A₂ phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1393

2-Methoxybenzoic acid NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification Cancer	Carbonic Anhydrase Phospholipase
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether) is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A₂ phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .

HY-N1393R

2-Methoxybenzoic acid (Standard) NSC 3778 (Standard); O-Methylsalicylic acid (Standard); Salicylic acid methyl ether (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Carbonic Anhydrase Phospholipase
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether) (Standard) is the analytical standard of 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A₂ phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .

Cat. No.	Product Name	Chemical Structure

HY-N1393S

2-Methoxybenzoic acid-13C6
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)- ¹³C₆ is the ¹³C-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A₂ phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .

2-Methoxybenzoic acid-13C6

2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)- ¹³C₆ is the ¹³C-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A₂ phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .

HY-N1393S1

2-Methoxybenzoic acid-d3
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)-d₃ is deuterium-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A₂ phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .

2-Methoxybenzoic acid-d3

2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)-d₃ is deuterium-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A₂ phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks